Investors

Financial Reports

Financial reporting and company disclosures.

Curasight A/S
Interim report Q2 2026

Latest report

Interim report Q2 2026

Access Curasight’s annual reports, interim reports and other published financial information.

Published
27 August 2026
Format
PDF
Download PDF

Annual reports

Annual Report 2025
26 February 2026
PDF
Annual Report 2024
25 April 2025
PDF
Annual Report 2023
22 February 2024
PDF
Annual Report 2022
23 February 2023
PDF
Annual Report 2021
24 February 2022
PDF
Annual Report 2020
24 February 2021
PDF
Annual Report 2019
PDF
Annual Report 2018
PDF

Interim reports

Interim report Q2 2026
27 August 2026
PDF
Interim report Q1 2026
28 May 2026
PDF
Year-end report Q4 2025
26 February 2026
PDF
Interim report Q3 2025
27 November 2025
PDF
Half-year report Q2 2025
28 August 2025
PDF
Interim report Q1 2025
25 April 2025
PDF
Year-end report Q4 2024
27 February 2025
PDF
Interim report Q3 2024
21 November 2024
PDF
Interim report Q2 2024
22 August 2024
PDF
Interim report Q1 2024
23 May 2024
PDF
Year-end report Q4 2023
22 February 2024
PDF
Interim report Q3 2023
23 November 2023
PDF
Interim report Q2 2023
24 August 2023
PDF
Interim report Q1 2023
25 May 2023
PDF
Year-end report Q4 2022
23 February 2023
PDF
Interim report Q3 2022
24 November 2022
PDF
Interim report Q2 2022
25 August 2022
PDF
Interim report Q1 2022
24 May 2022
PDF
Year-end report Q4 2021
24 February 2022
PDF
Interim report Q3 2021
25 November 2021
PDF
Interim report Q2 2021
24 August 2021
PDF
Interim report Q1 2021 – correction
20 May 2021
PDF
Interim report Q1 2021
20 May 2021
PDF
Year-end report Q4 2020
24 February 2021
PDF
Interim report Q3 2020
30 November 2020
PDF

Investor information

Investors

Financial Calendar

Key reporting dates and investor events.

Investors

General Meetings

Information for shareholders before and after Curasight general meetings.

Investors

Corporate Presentation

The latest Curasight investor presentation.

Seeing cancer. Treating cancer.

Investigational product statementTherapeutic product candidates within the uTRACE® and uTREAT® platform are investigational and they have currently not been approved for commercial use by any regulatory authority.

Forward-looking informationCertain information on this website may contain forward-looking statements regarding development plans, clinical milestones, regulatory activities, partnerships and other future events. Such statements involve risks and uncertainties, and actual outcomes may differ materially. Users should refer to Curasight’s latest market announcements and financial reports for current information.

Medical information statementInformation on this website is provided for general corporate and scientific information only and is not intended as medical advice. Patients should consult qualified healthcare professionals regarding diagnosis and treatment decisions.

+45 22 83 01 60 · info@curasight.com
Copyright 2026 © Curasight